



# Pharmaids Pharmaceuticals Limited

4-4-211/212/11-12, Inderbagh, Hyderabad - 500 095

Email: mailpharmaids@yahoo.co.in, Website: www.pharmaids.com

CIN No. L52520TG1989PLC009679

## STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED 31ST MARCH 2016

### PART-I

Particulars	QUARTER ENDED			YEAR ENDED	
	31.03.2016	31.12.2015	31.03.2015	31.03.2016	31.03.2015
<b>1 Income from Operations</b>	<b>AUDITED</b>	<b>UN AUDITED</b>		<b>AUDITED</b>	
(a) Net Sales/Income from operations	26.55	52.75	31.94	168.45	173.04
(b) Other Operating Income	0.00	0.00	0.00	0.00	0.00
<b>Total Income from Operations</b>	<b>26.55</b>	<b>52.75</b>	<b>31.94</b>	<b>168.45</b>	<b>173.04</b>
<b>2 Expenses</b>					
a. Consumption of raw materials	0.00	0.00	0.00	0.00	0.00
b. Purchases of stock-in-trade	25.66	35.89	10.94	114.51	104.19
c. Increase/decrease in stock in trade and WIP	5.24	(5.01)	13.56	0.89	(0.50)
d. Power & Fuel	0.00	0.00	0.00	0.00	0.00
e. Sales Tax and other Taxes	0.00	0.00	0.00	0.00	0.00
f. Employees Cost	3.70	5.35	3.25	20.30	18.20
g. Depreciation	2.91	2.52	8.67	10.37	13.71
h. Other expenditure	8.01	35.28	11.76	67.29	60.31
<b>Total</b>	<b>45.52</b>	<b>74.03</b>	<b>48.18</b>	<b>213.36</b>	<b>195.91</b>
(Any item exceeding 10% of the total expenditure to be shown separately)	0.00	0.00	0.00	0.00	0.00
<b>3 Profit / (Loss) from Operations before other Income, finance costs and Exceptional Items (1-2)</b>	<b>(18.97)</b>	<b>(21.28)</b>	<b>(16.24)</b>	<b>(44.91)</b>	<b>(22.87)</b>
<b>4 Other Income</b>	<b>0.00</b>	<b>0.06</b>	<b>0.00</b>	<b>4.57</b>	<b>12.42</b>
<b>Profit / (Loss) from Ordinary activities before finance costs and exceptional items</b>	<b>(18.97)</b>	<b>(21.28)</b>	<b>(16.24)</b>	<b>(40.34)</b>	<b>(10.45)</b>
<b>5 Finance Cost</b>	<b>1.03</b>	<b>1.00</b>	<b>0.15</b>	<b>2.87</b>	<b>0.15</b>
<b>7 Profit / (Loss) from Ordinary activities after finance costs but before exceptional items</b>	<b>(20.00)</b>	<b>(22.28)</b>	<b>(16.39)</b>	<b>(43.21)</b>	<b>(10.60)</b>
<b>8 Exceptional Items - Expenditure / (Income)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>9 Profit / (Loss) from Ordinary Activities before tax</b>	<b>(20.00)</b>	<b>(22.28)</b>	<b>(16.39)</b>	<b>(43.21)</b>	<b>(10.60)</b>
<b>10 Tax expense</b>					
a) Provision for Taxation	0.00	0.00	0.00	0.00	0.00
b) Provision for Deferred tax	0.00	0.00	0.00	3.45	4.05
c) MAT Credit	0.00	0.00	0.00	0.00	0.00
<b>11 Net Profit (+)/ Loss (-) from ordinary activities after tax</b>	<b>(20.00)</b>	<b>(22.28)</b>	<b>(16.39)</b>	<b>(39.76)</b>	<b>(6.55)</b>
<b>12 Extraordinary items (net of tax expense Rs.Nil )</b>	<b>Nil</b>	<b>Nil</b>	<b>Nil</b>	<b>Nil</b>	<b>Nil</b>
<b>13 Net Profit (+)/Loss (-) for the period</b>	<b>(20.00)</b>	<b>(22.28)</b>	<b>(16.39)</b>	<b>(39.76)</b>	<b>(6.55)</b>
<b>14 Paid-up equity share capital (Face value of the Share is Rs 10/- each)</b>	<b>336.31</b>	<b>336.31</b>	<b>336.31</b>	<b>336.31</b>	<b>336.31</b>
<b>15 Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year</b>	<b>9.94</b>	<b>9.94</b>	<b>9.94</b>	<b>9.94</b>	<b>9.94</b>
<b>16 Earnings Per Share (before &amp; after extraordinary items - not annualised)</b>					
a) Basic	(0.59)	(0.65)	(0.48)	(1.17)	(0.19)
b) Diluted	(0.59)	(0.65)	(0.48)	(1.17)	(0.19)

1. The above Audited Financial Results of the company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 27th May, 2016.

2) Amount for the quarter ended 31 March 2016 and 31 March 2015 represents the balancing amount between the audited amounts for the financial year and the published year to date amounts up to the third quarter of the current and previous financial year respectively.

3) The company operates in a single segment and the results pertain to a single segment. i.e., drug formulation only.

4) There were no investor complaints pending at the beginning of the quarter and no investor complaint was received and remained pending at the end of the said quarter

5) Figures for the previous period have been re-grouped or re-arranged wherever considered necessary.

For PHARMAIDS PHARMACEUTICALS LIMITED

*Ghishulal Jain*

Sd/- Dr. Ghishulal Jain

Chairman & Managing Director



PLACE : HYDERABAD

DATE : 27.05.2016



# FORM A

(For audit report with unmodified opinion)  
[Pursuant to Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015]

1.	Name of the Company	Pharmaids Pharmaceuticals Limited
2.	Annual financial statements for the year ended	31 <sup>st</sup> March, 2016
3.	Type of Audit observation	unmodified
4.	Frequency of observation	Not Applicable
5.	To be Signed by	Signature
	For Pharmaids Pharmaceuticals Limited	
	Dr. Ghisulal Jain Managing Director	<i>Ghisulal Jain</i> Managing Director
	For Rakesh S Jain & Associates (Firm Regn No 010129S)	<i>B. Ramesh Kumar</i>
	B Ramesh Kumar Partner M .No 200304 Auditor of Company	
	M Sudheer Audit Committee Chairman	<i>Sudheer</i> 





**RAKESH S JAIN & ASSOCIATES**  
CHARTERED ACCOUNTANTS

3-191, Nagar Khana, Begum Bazar,  
DERABAD - 500 012. (A.P.) INDIA

E-mail : rsjainassociates@rediffmail.com  
Fax : 040-24617420  
Suresh Kumar Jain (Mob) : +91-9849025612  
B. Ramesh Kumar (Mob) : +91-9849025641

Date :

Auditor's Report On Quarterly Financial Results and Year to Date Results of M/s Pharmaids Pharmaceuticals Limited pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015

To  
**Board of Directors**  
**M/s Pharmaids Pharmaceuticals Limited**  
**Hyderabad**

We have audited the quarterly financial results of **M/s Pharmaids Pharmaceuticals Limited** for the quarter ended **31<sup>st</sup> March 2016** and the year to date results for the period **01<sup>st</sup> April 2015 to 31<sup>st</sup> March 2016** attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued there under; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.


We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly standalone financial results as well as the year to date results:

- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- (ii) give a true and fair view of the loss and other financial information for the quarter ended 31<sup>st</sup> March, 2016 as well as the year to date results for the period from 01<sup>st</sup> April 2015 to 31<sup>st</sup> March 2016

For **RAKESH S JAIN & ASSOCIATES**  
Chartered Accountants  
Firm Registration no.:0101295

*B. Ramesh Kumar*  
(B. Ramesh Kumar)  
Partner  
M.No: 200304



Place: Hyderabad  
Date: 27/05/2016